Adverse effects of incretin therapy for type 2 diabetes [6]

JAMA

Volumn 298, Issue 15, 2007, Pages 1759-1760

  Grouzmann, Eric ^a   Monod, Michel ^a   Landis, Basil N ^b   Lacroix, Jean Silvain ^b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSAICIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; HISTAMINE; INCRETIN; SUBSTANCE P;

CHRONIC SINUSITIS; CONFIDENCE INTERVAL; DRUG EFFICACY; DRUG SAFETY; ENZYME ACTIVITY; HEADACHE; HUMAN; INFLAMMATORY CELL; LETTER; NON INSULIN DEPENDENT DIABETES MELLITUS; NOSE CONGESTION; NOSE MUCOSA; PRIORITY JOURNAL; RHINOPHARYNGITIS; RHINOSINUSITIS;

EID: 35348961958     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.298.15.1759-b     Document Type: Letter

References (3)

1. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007;298(2):194-206.
2. Grouzmann E, Monod M, Landis B, et al. Loss of dipeptidylpeptidase IV activity in chronic rhinosinusitis contributes to the neurogenic inflammation induced by substance P in the nasal mucosa. FASEB J. 2002;16(9):1132- 1134.
3. Fusayasu E, Kowa H, Takeshima T, Nakaso K, Nakashima K. Increased plasma substance P and CGRP levels, and high ACE activity in migraineurs during headache-free periods. Pain. 2007;128(3):209-214.